Clinical Oncology
Volume 21, Issue 3 , Pages 175-182 , April 2009

Clinical Impact of Computed Tomography-based Image-guided Brachytherapy for Cervix Cancer using the Tandem-ring Applicator — the Addenbrooke's Experience

  • L.T. Tan

      Affiliations

    • Corresponding Author InformationAuthor for correspondence: L. T. Tan, Oncology Centre, Box 193, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge CB2 0QQ, UK. Tel: +44-1223-245151; Fax: +44-1223-274409.
    • ,
  • C.E. Coles
    • ,
  • C. Hart
    • ,
  • E. Tait

Received 23 September 2008 ,Revised 12 November 2008 ,Accepted 2 December 2008.

References 

  1. Pearcey R, Miao Q, Kong W, et al. Impact of adoption of chemoradiotherapy on the outcome of cervical cancer in Ontario: results of a population-based cohort study. J Clin Oncol. 2007;25:2383–2388
  2. Kirwan JM, Symonds P, Green JA, et al. A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer. Radiother Oncol. 2003;68:217–226
  3. Tan LT, Zahra M. Long-term survival and late toxicity after chemoradiotherapy for cervical cancer—the Addenbrooke's experience. Clin Oncol (R Coll Radiol). 2008;20:358–364
  4. Potter R, Knocke TH, Fellner C, et al. Definitive radiotherapy based on HDR brachytherapy with iridium 192 in uterine cervix carcinoma: report on the Vienna University Hospital findings (1993–1997) compared to the preceding period in the context of ICRU 38 recommendations. Cancer Radiother. 2000;4:159–172
  5. Potter R, Dimopoulos J, Georg P, et al. Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer. Radiother Oncol. 2007;83:148–155
  6. Jewell EL, Kulasingam S, Myers ER, et al. Primary surgery versus chemoradiation in the treatment of IB2 cervical carcinoma: a cost effectiveness analysis. Gynecol Oncol. 2007;107:532–540
  7. Micha JP, Goldstein BH, Rettenmaier MA, et al. Surgery alone or surgery with a combination radiation or chemoradiation for management of patients with bulky-stage IB2 cervical carcinoma. Int J Gynecol Cancer. 2006;16:1147–1151
  8. Moore DH. Treatment of stage IB2 (bulky) cervical carcinoma. Cancer Treat Rev. 2003;29:401–406
  9. Rocconi RP, Estes JM, Leath CA, et al. Management strategies for stage IB2 cervical cancer: a cost-effectiveness analysis. Gynecol Oncol. 2005;97:387–394
  10. Rutledge TL, Kamelle SA, Tillmanns TD, et al. A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference?. Gynecol Oncol. 2004;95:70–76
  11. Ryu HS, Kang SB, Kim KT, et al. Efficacy of different types of treatment in FIGO stage IB2 cervical cancer in Korea: results of a multicenter retrospective Korean study (KGOG-1005). Int J Gynecol Cancer. 2007;17:132–136
  12. Yessaian A, Magistris A, Burger RA, Monk BJ. Radical hysterectomy followed by tailored postoperative therapy in the treatment of stage IB2 cervical cancer: feasibility and indications for adjuvant therapy. Gynecol Oncol. 2004;94:61–66
  13. Zivanovic O, Alektiar KM, Sonoda Y, et al. Treatment patterns of FIGO stage IB2 cervical cancer: a single-institution experience of radical hysterectomy with individualized postoperative therapy and definitive radiation therapy. Gynecol Oncol, in press.
  14. Kirisits C, Potter R, Lang S, et al. Dose and volume parameters for MRI-based treatment planning in intracavitary brachytherapy for cervical cancer. Int J Radiat Oncol Biol Phys. 2005;62:901–911
  15. Potter R, Haie-Meder C, Van Limbergen E, et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy—3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol. 2006;78:67–77
  16. Brooks S, Bownes P, Lowe G, et al. Cervical brachytherapy utilizing ring applicator: comparison of standard and conformal loading. Int J Radiat Oncol Biol Phys. 2005;63(3):934–939
  17. De Brabandere M, Mousa AG, Nulens A, et al. Potential of dose optimisation in MRI-based PDR brachytherapy of cervix carcinoma. Radiother Oncol. 2008;88:217–226
  18. Lindegaard JC, Tanderup K, Nielsen SK, et al. MRI-guided 3D optimization significantly improves DVH parameters of pulsed-dose-rate brachytherapy in locally advanced cervical cancer. Int J Radiat Oncol Biol Phys. 2008;71:756–764
  19. Potter R, Fidarova E, Kirisits C, Dimopoulos J. Image-guided adaptive brachytherapy for cervix carcinoma. Clin Oncol (R Coll Radiol). 2008;20:426–432
  20. Haie-Meder C, Potter R, Van Limbergen E, et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol. 2005;74:235–245
  21. Nag S. Controversies and new developments in gynecologic brachytherapy: image-based intracavitary brachytherapy for cervical carcinoma. Semin Radiat Oncol. 2006;16:164–167
  22. Dimopoulos J, Georg P, Kirisits C, et al. The predictive value of dose volume parameters on local tumor control in MRI assisted brachytherapy of cervix cancer. Radiother Oncol. 2006;81(Suppl 1):abstract 101, S39
  23. Georg P, Dimopoulos J, Kirisits C, et al. Dose volume parameters in cervical cancer patients treated with MRI based brachytherapy and their predictive value for late adverse side effects in rectum, sigmold and bladder. Radiother Oncol. 2006;81(Suppl 1):abstract 100, S38–S39
  24. Viswanathan AN, Dimopoulos J, Kirisits C, et al. Computed tomography versus magnetic resonance imaging-based contouring in cervical cancer brachytherapy: results of a prospective trial and preliminary guidelines for standardized contours. Int J Radiat Oncol Biol Phys. 2007;68:491–498
  25. Wachter-Gerstner N, Wachter S, Reinstadler E, et al. The impact of sectional imaging on dose escalation in endocavitary HDR-brachytherapy of cervical cancer: results of a prospective comparative trial. Radiother Oncol. 2003;68:51–59
  26. Nucletron Press Release. Nucletron announces advances in image-guided adaptive brachytherapy technology for gynecologic cancers through partnership with AKH/MUW Vienna. Nucletron: Veenendaal, Netherlands, 8 September, 2008.

PII: S0936-6555(08)00460-3

doi: 10.1016/j.clon.2008.12.001

Clinical Oncology
Volume 21, Issue 3 , Pages 175-182 , April 2009

Article Tools

* Image Usage & Resolution